Skip to main content

Table 1 Patients characteristics in our study cohort

From: The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas

Variable   Group 1
Oligodendroglioma,
IDH-mutant and 1p19q–codeletion
WHO grade II & III
Group 2
Anaplastic astrocytoma,
IDH-mutant,
WHO grade III
Group 3
Glioblastoma, IDH-mutant,
WHO grade IV
Group 4
Anaplastic astrocytoma,
IDH-wildtype,
WHO grade III
Group 5
Glioblastoma
IDH-wildtype
WHO grade IV
  No n (%) n (%) n (%) n (%) n (%)
Number of Patients 168 65 (100) 23 (100) 13 (100%) 15 (100%) 52 (100%)
Age (years) Mean (range) 43.4 (21–65) 42.6 (21–65) 39 (29–49) 48.6 (26–72) 55.3 (27–79)
Gender Male 33 (50.8) 17 (73.9) 9 (69.2) 6 (40) 35 (66.0)
Female 32 (49.2) 6 (26.1) 4 (30.8) 9 (60) 17 (34.0)
Mean OS (mo)   38.0 (0–95) 59.4 (0.5–114.8) 40.0 (11.8–72.3) 28.2 (0.5–76.9) 19.6 (0.5–116)
Mean PFS (mo)   38.0 (1–96) 48.7 (0.5–114.8) 36.0 (9.5–68.7) 13.8 (0.5–76.9) 15.4 (0–103)
TERT sequencing Wildtype 2 (3.1) 22 (95.6) 3 (23.1) 12 (80) 11 (21.2)
Mutant 63 (96.9) 1 (4.4) 10 (76.9) 3 (20) 41 78.8)
1p, 19q FISH No co-deletion 0 (0) 0 (0) 13 (100) 15 (100) 53 (100)
Co-deletion 65 (100) 23 (100) 0 (0) 0 (0) 0 (0)
ATRX IHC Wildtype (retained)
Mutant (loss)
0 (0)
65 (100)
7 (30.4)
16 (69.6)
4 (30.7)
9 (69.2)
9 (60)
6 (40)
48 (92.3)
4 (7.7)
MGMT MSP No methylation 11 (16.9) 9 (39.1) 3 (23.1) 7 (46.7) 26 (50.0)
Methylation 54 (83.1) 14 (60.9) 10 (76.9) 8 (53.3) 26 (50.0)
Ki-67 labeling index (%) Mean (range) 10.6 (1.5–39.5) Not available 14 (1–39.3) Not available 20.6 (0–54.8)
  1. Abbreviations: mo month, OS overall survival, PFS progression free survival, FISH fluorescent in situ hybridization, IHC immunohistochemistry, MSP methylation-specific PCR, HD homozygous deletion, WHO World Health Organization
\